These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22505587)

  • 21. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
    J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.
    Tripodo C; Petta S; Guarnotta C; Pipitone R; Cabibi D; Colombo MP; Craxì A
    Antivir Ther; 2012; 17(1):111-8. PubMed ID: 22267475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
    Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P
    J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
    Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
    Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
    Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
    J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
    Stättermayer AF; Stauber R; Hofer H; Rutter K; Beinhardt S; Scherzer TM; Zinober K; Datz C; Maieron A; Dulic-Lakovic E; Kessler HH; Steindl-Munda P; Strasser M; Krall C; Ferenci P
    Clin Gastroenterol Hepatol; 2011 Apr; 9(4):344-350.e2. PubMed ID: 20728570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
    J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
    Yu ML; Huang CF; Huang JF; Chang NC; Yang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Li YN; Wu MS; Dai CY; Juo SH; Chuang WL
    Hepatology; 2011 Jan; 53(1):7-13. PubMed ID: 21254157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
    World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
    Sarrazin C; Susser S; Doehring A; Lange CM; Müller T; Schlecker C; Herrmann E; Lötsch J; Berg T
    J Hepatol; 2011 Mar; 54(3):415-21. PubMed ID: 21112657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
    Falleti E; Bitetto D; Fabris C; Fattovich G; Cussigh A; Cmet S; Ceriani E; Fornasiere E; Pasino M; Ieluzzi D; Pirisi M; Toniutto P
    Hepatology; 2012 Nov; 56(5):1641-50. PubMed ID: 22610885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.
    Aghemo A; Degasperi E; Rumi MG; Galmozzi E; Valenti L; De Francesco R; De Nicola S; Cheroni C; Grassi E; Colombo M
    Biomed Res Int; 2013; 2013():580796. PubMed ID: 23936821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.